Jump to: Page Content, Section Navigation, Site Navigation, Site Search, Account Information, or Site Tools.
|
|
Sci. Signal., 8 December 2009 EDITORS' CHOICE
>
Pharmacology Better Alzheimers OptionsNancy R. Gough Science Signaling, AAAS, Washington, DC 20005, USA
Disruption of synaptic plasticity, specifically long-term potentiation (LTP), by the β-amyloid (Aβ) protein may contribute to the cognitive and memory defects associated with Alzheimers disease. Memantine is a low-affinity antagonist of N-methyl-D-aspartate (NMDA) receptors that is approved for treatment of Alzheimers dementia, but the doses that prevent Aβ-mediated disruption of LTP can also inhibit LTP on their own. Thus, Hu et al. tested in mice several antagonists that were more selective for NMDA receptors of particular subunit composition to determine whether one would be more effective at blocking Aβ-mediated inhibition of LTP yet would not impair LTP production alone. When coinjected intracerebroventricularly or systemically with an Aβ fragment, antagonists specific for the NR2B (also known as the GluN2B) subunit prevented Aβ-mediated inhibition of LTP at concentrations that did not disrupt LTP when injected alone. Because in vitro data suggest that the Aβ-mediated effect on LTP is indirect, involving release of tumor necrosis factor– N.-W. Hu, I. Klyubin, R. Anwy, M. J. Rowan, GluN2B subunit-containing NMDA receptor antagonists prevent Aβ-mediated synaptic plasticity disruption in vivo. Proc. Natl. Acad. Sci. U.S.A. 106, 20504–20509 (2009). [Abstract] [Full Text]
Citation: N. R. Gough, Better Alzheimers Options. Sci. Signal. 2, ec392 (2009). The editors suggest the following Related Resources on Science sites:In Science Signaling
|
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882